In Depth

Psychedelic drug developers redesign trials to avoid Lykos faux pas

Can pharma tariffs “Make America Manufacture Again”?

Policy changes and digital strategies guide oncology research

The European Market Access Lag: 2021–2024

Vutrisiran marks first silencer approved for ATTR-CM

ASCO 2025: Key highlights